Clinical trials: Portal Vein Thrombosis
Liver Cirrhosis, Portal Vein Thrombosis
Efficacy and Safety of Anticoagulant Therapy in Portal Vein Thrombosis
The study is aimed at evaluating the efficacy and safety of anticoagulant therapy with nadroparin calcium and warfarin in patients with portal vein thrombosis (PVT).
- Trial name
- NCT04173429
- Testing
- Nadroparin calcium, warfarin
- Where
- China
- Volunteers
- 64 people
- Sponsor
- Qilu Hospital of Shandong University
Portal Vein Tumor Thrombus
A Trial to Compare Surgery With Sorafenib for Hepatic Celluler Cancer With Portal Vein Tumor Thrombosis
According to the guidelines recommended, only a few new targeted therapy drugs treatment, such as Sorafenib, is proper. It's 3 year survival rate is only 8% or so.
- Trial name
- NCT03178656
- Testing
- Sorafenib, surgery
- Where
- China
- Volunteers
- 54 people
- Sponsor
- Huazhong University of Science and Technology
Hepatocellular Carcinoma (HCC)
Outcome of Transarterial Chemo-embolization (TACE) in Hepatocellular Carcinoma Patients With Partial Portal Vein Thrombosis
Portal vein tumor invasion (PVT) is a common complication in HCC. the studyb Aimed to assess the outcomes after TACE in patients with branch PVT regarding Child classification, radiological response and 1 year survival.
- Trial name
- NCT03007212
- Testing
- transarterial chemoembolization versus the standard treatment with sorafinib
- Volunteers
- 30 people
- Sponsor
- Ain Shams University
Portal Vein Thrombosis
Efficacy and Safety of Rivaroxaban in the Management of Acute Non-neoplastic PVT Compensated Cirrhosis
-Rivaroxaban is factor Xa inhibitor
- Trial name
- NCT03193502
- Testing
- rivaroxaban
- Where
- Egypt
- Volunteers
- 40 people
- Sponsor
- Sherief Abd-Elsalam
Thrombosis Portal Vein
TIPS or Anticoagulation in Portal Vein Thrombosis
The PROGRESS is an investigator-initiated, multicentre, randomized, trial comparing anticoagulation, which is the currently most frequently used treatment, alone, versus transjugular intrahepatic portosystemic shunt (TIPS)…
- Trial name
- PROGRESS (NCT03422419)
- Testing
- Heparin, TIPS
- Sponsor
- Insel Gruppe AG, University Hospital Bern
Localized Resectable Adult Primary Liver Cancer, Stage III Childhood Liver Cancer
Surgery With or Without Hepatic Arterial Chemotherapy in Treating Patients With Liver Cancer
RATIONALE: Drugs used in chemotherapy, such as fluorouracil and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00238160
- Testing
- cisplatin, fluorouracil, adjuvant therapy
- Where
- 4 sites in Japan
- Sponsor
- Kyoto University
Carcinoma, Hepatocellular
Study of Folfox4 Chemotherapy Regimen to Prevent Early Postoperative Recurrence for HCC-PVTT Patients
This study is to investigate the efficacy and safety of Folfox4 chemotherapy regimen to prevent early recurrence for hepatocellular carcinoma patients with portal vein tumor thrombus following curative resection
- Trial name
- NCT02813096
- Testing
- folfox4 chemotherapy regimen
- Volunteers
- 500 people
- Sponsor
- Guangxi Medical University
Hepatocellular Carcinoma With Portal Vein Thrombosis
Non-selective Beta Blockers Versus EVL for Primary Prophylaxis of Esophageal Variceal Bleeding in Patients With Hepatocellular Carcinoma With Portal Vein Tumour Thrombosis.
Every patient with HCC (Hepato-Cellular Carcinoma) with main portal vein thrombosis will be screened for presence of large esophageal varices and will be randomized between non-selective beta blocker versus primary endoscopic…
- Trial name
- NCT01659346
- Testing
- Endoscopic Variceal Ligation, Carvedilol
- Where
- India
- Sponsor
- Institute of Liver and Biliary Sciences, India
Hepatocellular Carcinoma, Portal Vein Tumor Thrombosis
Safety and Efficacy of Radiotherapy Plus Sintilimab for HCC With Portal Vein Tumor Thrombosis
The proposed study is an open-label, single-center, single arm phase 1b study to evaluate the safety and efficacy of radiotherapy plus sintilimab for HCC with PVTT.
- Trial name
- NCT04104074
- Testing
- Radiotherapy, Sintilimab
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Beijing Tsinghua Chang Gung Hospital
Hepatocellular Carcinoma
A Study to Evaluate Sintilimab Plus Lenvatinib as Adjuvant Therapy in Hepatocellular Carcinoma With Portal Vein Tumor Thrombosis (PVTT) After Surgical Resection
To compare the impact on recurrence risk of adjuvant Sintilimab (a recombinant fully human anti-PD-1 monoclonal antibody) plus Lenvatinib for patients with hepatocellular carcinoma and portal vein tumor thrombus (PVTT ) after…
- Trial name
- NCT06089382
- Testing
- Sintilimab, Lenvatinib, Transarterial Chemoembolization (TACE)
- Where
- China
- Volunteers
- 104 people
- Sponsor
- Tongji Hospital
Hepatocellular Carcinoma
HR Combined With FOLFOX4 for HCC With PVTT
Hepatocellular carcinoma (HCC) is the sixth most common cancer and the third most frequent cause of cancer death worldwide. Hepatic resection (HR) is the conventional ''curative'' treatment for HCC.
- Trial name
- NCT02452853
- Testing
- HR, FOLFOX4
- Volunteers
- 51 people
- Sponsor
- Sun Yat-sen University
Hepatocellular Carcinoma
Toripalimab Plus Stereotactic Body Radiotherapy for HCC With PVTT
To explore the efficacy and safety of toripalimab plus stereotactic body radiotherapy for hepatocellular carcinom with portal vein tumor thrombus.
- Trial name
- NCT04169399
- Testing
- Toripalimab, Stereotactic body radiotherapy
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Sun Yat-sen University
Hepatecellular Carcinoma, RALOX-HAIC（Hepatic Arterial Infusion Chemotherapy With Raltitrexed and Oxaliplatin
QL1706 in Combination With Bevacizumab and RALOX HAIC for Hepatocellular Carcinoma With Vp3/4 PVTT
The goal of this prospective, single-arm, multi-center Phase II clinical trial is to evaluate the clinical efficacy and safety of QL1706 combined with bevacizumab and RALOX hepatic artery infusion chemotherapy in treating liver…
- Conditions
- Hepatecellular Carcinoma, RALOX-HAIC（Hepatic Arterial Infusion Chemotherapy With Raltitrexed and Oxaliplatin, Bevacizumab, Type VP3/4 Portal Vein Tumor Thrombosis
- Trial name
- NCT07327788
- Testing
- Iparomlimab and Tuvonralimab Injection (QL1706), Bevacizumab, Hepatic Arterial Infusion Chemotherapy with Raltitrexed and Oxaliplatin (RALOX-HAIC)
- Where
- China
- Volunteers
- 38 people
- Sponsor
- Nanfang Hospital, Southern Medical University
Liver Cancer
Clinical Study of Radiotherapy Combined With Camrelizumab and Apatinib in the Treatment of Liver Cancer Patients .
Clinical study of radiotherapy combined with Camrelizumab and Apatinib in the treatment of liver cancer patients with VP4.
- Trial name
- NCT06632522
- Testing
- radiotherapy combined with Camrelizumab and Apatinib
- Where
- China
- Volunteers
- 46 people
- Sponsor
- Beijing Tsinghua Chang Gung Hospital
Liver Cirrhosis, Portal Vein Thrombosis
Portal Vein Thrombosis in Liver Cirrhosis: Clinical Characteristics, Radiological Patterns, and Predictors
Portal vein thrombosis (PVT) is a common complication in patients with liver cirrhosis and is associated with increased morbidity due to worsening portal hypertension and hepatic decompensation.
- Trial name
- Thrombosis (NCT07560202)
- Testing
- Abdominal US, Doppler US and abdominal multi-slice computed tomography (MSCT) with contrast was performed
- Where
- Egypt
- Volunteers
- 240 people
- Sponsor
- Elham Ahmed Hassan
Extrahepatic Portal Vein Obstruction (EHPVO), Thrombophilia
Hematological Disorders in EHPVO Patients
This study focuses on patients who have a condition called extrahepatic portal vein obstruction (EHPVO), where a blood clot blocks the portal vein outside the liver.
- Conditions
- Extrahepatic Portal Vein Obstruction (EHPVO), Thrombophilia, Myeloproliferative Neoplasms (MPN), Antiphospholipid Syndrome (APS)
- Trial name
- EHPVO-HEM (NCT07108023)
- Testing
- No intervention (Observational Study)
- Volunteers
- 115 people
- Sponsor
- Rahab Nady
Hepato Cellular Carcinoma (HCC), Portal Vein Tumour Thrombosis
PIVKA-II for Predicting Portal Vein Thrombosis in Hepatocellular Carcinoma
The goal of this cross-sectional observational study is to evaluate the relation between Prothrombin induced by vitamin K absence II (PIVKA-II) and the presence of portal vein tumor thrombosis (PVTT) in hepatocellular carcinoma…
- Trial name
- NCT06960954
- Testing
- Prothrombin induced by vitamin K absence II (PIVKA-II)
- Where
- Egypt
- Volunteers
- 116 people
- Sponsor
- Tanta University
HCC
SBRT With Immunotherapy and Atezo-Bev in HCC With Major Portal Vein Thrombosis
Patients with PVTT involvement is a significant healthcare burden as they are present in up to 40% of patients with HCC at diagnosis.
- Trial name
- NCT06823375
- Testing
- Radiotherapy, Atezolizumab plus Bevacizumab
- Where
- 2 sites in Hong Kong
- Volunteers
- 40 people
- Sponsor
- Chinese University of Hong Kong
Unresectable Hepatocellular Cancer, Portal Vein Tumor Thrombus
Sorafenib Plus Toripalimab for Unresectable HCC With Portal Vein Tumor Thrombus
This study aims to evaluate the efficacy and safety of sorafenib plus toripalimab for unresectable hepatocellular carcinoma (HCC) with portal vein tumor thrombus (PVTT).
- Trial name
- STUHCCPVTT (NCT04069949)
- Testing
- sorafenib; toripalimab
- Volunteers
- 39 people
- Sponsor
- Sichuan University
Cirrhosis, Portal Vein Thrombosis
Safety of Anticoagulant Therapy After Endoscopic Treatment
The investigators aimed to verify the efficacy and safety of nadroparin calcium warfarin sequential (NWS) anticoagulation therapy after endoscopic therapy in PVT patients with cirrhosis and AVB.
- Conditions
- Cirrhosis, Portal Vein Thrombosis, Esophageal and Gastric Varices, Anticoagulant-induced Bleeding
- Trial name
- NCT04976543
- Testing
- nadroparin calcium-warfarin sequential anticoagulation
- Where
- China
- Volunteers
- 86 people
- Sponsor
- Qilu Hospital of Shandong University